COVID-19 vaccine design: the Janus face of immune enhancement
Top Cited Papers
- 28 April 2020
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 20 (6) , 347-348
- https://doi.org/10.1038/s41577-020-0323-4
Abstract
Previous work on severe acute respiratory syndrome coronavirus (SARS-CoV) vaccines identified cellular immunopathology and antibody-dependent enhancement as potential safety issues. We discuss the implications of these findings for COVID-19 vaccine development and our approach to optimizing for safety and efficacy. Here, Hotez and colleagues highlight the two ‘faces’ of immune enhancement that could impact COVID-19 vaccine design.Keywords
This publication has 9 references indexed in Scilit:
- The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancementMicrobes and Infection, 2020
- The COVID-19 vaccine development landscapeNature Reviews Drug Discovery, 2020
- Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccineCellular & Molecular Immunology, 2020
- Viral-Induced Enhanced Disease IllnessFrontiers in Microbiology, 2018
- Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine CandidateJournal of Pharmaceutical Sciences, 2017
- Stop Press: Eosinophils Drafted to Join the Th17 TeamImmunity, 2015
- Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS VirusPLOS ONE, 2012
- Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patientsVirology Journal, 2010
- Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal modelPublished by Elsevier ,2006